Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

PF-06821497 Behandling av återfall/refraktär SCLC, kastrationsresistent prostatacancer och follikulärt lymfom

9 november 2026 uppdaterad av: Pfizer

EN FAS I DOSEKALATION OCH Utökad KOHORTSTUDIE AV PF-06821497 FÖR BEHANDLING AV VUXNA PATIENTER MED ÅTERKOMMANDE/REFRAKTÄR Småcellig lungcancer (SCLC), KASTRATIONSRESISTENT PROSTATACANCER (CRMPOLLIPCULÄR)

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.

Part 3, which is open for enrollment is seeking men who:

  • have Castration Resistant Prostate Cancer (CRPC) and
  • have previously received treatment for CRPC and have progressed from the last treatment

All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).

In the assessment phase:

  • participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
  • participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
  • participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.

After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.

The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.

Studieöversikt

Detaljerad beskrivning

This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).

Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.

Studietyp

Interventionell

Inskrivning (Beräknad)

453

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Haskovo, Bulgarien, 6300
        • Avslutad
        • Specialized Hospital for Active Treatment of Oncology - Haskovo
    • Arizona
      • Tucson, Arizona, Förenta staterna, 85719
        • Aktiv, inte rekryterande
        • Banner-University Medical Center Tucson
      • Tucson, Arizona, Förenta staterna, 85719
        • Aktiv, inte rekryterande
        • The University of Arizona Cancer Center-North Campus
      • Tucson, Arizona, Förenta staterna, 85724
        • Aktiv, inte rekryterande
        • The University of Arizona Cancer Center
      • Tucson, Arizona, Förenta staterna, 85741
        • Avslutad
        • Arizona Urology Specialists, PLLC
    • California
      • Anaheim, California, Förenta staterna, 92801
        • Aktiv, inte rekryterande
        • Pacific Cancer Medical Center INC
      • Duarte, California, Förenta staterna, 91010
        • Aktiv, inte rekryterande
        • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
      • Duarte, California, Förenta staterna, 91010
        • Aktiv, inte rekryterande
        • City of Hope Investigational Drug Services (IDS)
    • Connecticut
      • Norwalk, Connecticut, Förenta staterna, 06856
        • Aktiv, inte rekryterande
        • Norwalk Hospital
    • Kansas
      • Fairway, Kansas, Förenta staterna, 66205
        • Aktiv, inte rekryterande
        • The University of Kansas Cancer Center, Investigational Drug Services
      • Fairway, Kansas, Förenta staterna, 66205
        • Aktiv, inte rekryterande
        • The University of Kansas Clinical Research Center
      • Kansas City, Kansas, Förenta staterna, 66160
        • Aktiv, inte rekryterande
        • The University of Kansas Hospital
      • Kansas City, Kansas, Förenta staterna, 66160
        • Aktiv, inte rekryterande
        • The University of Kansas Medical Center Medical Office Building
      • Overland Park, Kansas, Förenta staterna, 66211
        • Aktiv, inte rekryterande
        • The University of Kansas Cancer Center - Indian Creek Campus
      • Westwood, Kansas, Förenta staterna, 66205
        • Aktiv, inte rekryterande
        • The University of Kansas Cancer Center
    • Kentucky
      • Louisville, Kentucky, Förenta staterna, 40202
        • Aktiv, inte rekryterande
        • Norton Cancer Institute, Norton Healthcare Pavilion
      • Louisville, Kentucky, Förenta staterna, 40202
        • Aktiv, inte rekryterande
        • Norton Hospital
      • Louisville, Kentucky, Förenta staterna, 40202
        • Aktiv, inte rekryterande
        • Norton Cancer Institute - Downtown
    • Maryland
      • Rockville, Maryland, Förenta staterna, 20850
        • Avslutad
        • Maryland Oncology Hematology, P.A.
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02215
        • Aktiv, inte rekryterande
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Förenta staterna, 02115
        • Aktiv, inte rekryterande
        • Brigham and Women's Hospital
      • Newton, Massachusetts, Förenta staterna, 02459
        • Aktiv, inte rekryterande
        • Dana Farber Cancer Institute- Chestnut Hill
    • Nebraska
      • Omaha, Nebraska, Förenta staterna, 68130
        • Rekrytering
        • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    • New Jersey
      • Hackensack, New Jersey, Förenta staterna, 07601
        • Aktiv, inte rekryterande
        • Hackensack University Medical Center
      • Hackensack, New Jersey, Förenta staterna, 07601
        • Aktiv, inte rekryterande
        • John Theurer Cancer Center at Hackensack University Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • Rekrytering
        • OU Health University of Oklahoma Medical Center
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • Rekrytering
        • Stephenson Cancer Center (chemo location)
    • South Carolina
      • Myrtle Beach, South Carolina, Förenta staterna, 29572
        • Rekrytering
        • Carolina Urologic Research Center
      • Myrtle Beach, South Carolina, Förenta staterna, 29572
        • Rekrytering
        • Parkway Surgery Center
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • Rekrytering
        • Sarah Cannon Research Institute - Pharmacy
      • Nashville, Tennessee, Förenta staterna, 37203
        • Rekrytering
        • SCRI Oncology Partners
    • Texas
      • Austin, Texas, Förenta staterna, 78705
        • Avslutad
        • Texas Oncology - Austin Midtown
      • Dallas, Texas, Förenta staterna, 75390
        • Aktiv, inte rekryterande
        • UT Southwestern Medical Center
      • Dallas, Texas, Förenta staterna, 75390
        • Aktiv, inte rekryterande
        • University of Texas Southwestern Medical Center - Simmons Cancer Center
      • Dallas, Texas, Förenta staterna, 75390
        • Aktiv, inte rekryterande
        • UT Southwestern University Hospital - William P. Clements, Jr
      • Dallas, Texas, Förenta staterna, 75390
        • Aktiv, inte rekryterande
        • UT Southwestern University Hospital - Zale Lipshy
      • Irving, Texas, Förenta staterna, 75063
        • Avslutad
        • US Oncology Investigational Product Center (IPC)
      • Irving, Texas, Förenta staterna, 75063
        • Avslutad
        • US Oncology Investigational Products Center
      • Irving, Texas, Förenta staterna, 75039
        • Rekrytering
        • NEXT Dallas
      • San Antonio, Texas, Förenta staterna, 78229
        • Rekrytering
        • NEXT Oncology
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22031
        • Aktiv, inte rekryterande
        • Virginia Cancer Specialists, PC
    • Washington
      • Port Angeles, Washington, Förenta staterna, 98362
        • Aktiv, inte rekryterande
        • Olympic Medical Center
      • Poulsbo, Washington, Förenta staterna, 98370
        • Aktiv, inte rekryterande
        • Fred Hutchinson Cancer Center Alliance Peninsula
      • Seattle, Washington, Förenta staterna, 98195
        • Aktiv, inte rekryterande
        • University of Washington Medical Center
      • Seattle, Washington, Förenta staterna, 98109
        • Aktiv, inte rekryterande
        • Fred Hutchinson Cancer Center
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • Aktiv, inte rekryterande
        • National Cancer Center Hospital East
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510120
        • Aktiv, inte rekryterande
        • The First Affiliated Hospital of Guangzhou Medical University
    • Hunan
      • Changsha, Hunan, Kina, 410013
        • Aktiv, inte rekryterande
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210009
        • Aktiv, inte rekryterande
        • Zhongda Hospital Southeast University
      • Nanjing, Jiangsu, Kina, 210008
        • Aktiv, inte rekryterande
        • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Rekrytering
        • West China Hospital, Sichuan University
    • Zhejiang
      • Wenzhou, Zhejiang, Kina, 325000
        • Aktiv, inte rekryterande
        • The First Affiliated Hospital of Wenzhou Medical University
      • Bydgoszcz, Polen, 85-048
        • Har inte rekryterat ännu
        • In-Vivo Sp. z o.o. In-vivo Bydgoszcz
      • Koszalin, Polen, 75-581
        • Aktiv, inte rekryterande
        • Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
      • Krakow, Polen, 30-348
        • Rekrytering
        • Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
      • Rzeszów, Polen, 35-326
        • Aktiv, inte rekryterande
        • Centrum Medyczne MEDYK
      • Warsaw, Polen, 02-781
        • Aktiv, inte rekryterande
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
      • Moscow, Ryssland, 117186
        • Aktiv, inte rekryterande
        • LLC "Neyro-klinika"
      • Moscow, Ryssland, 125284
        • Avslutad
        • Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
      • Moscow, Ryssland, 129301
        • Avslutad
        • SBHI of Moscow City Clinical Hospital
      • Omsk, Ryssland, 644013
        • Avslutad
        • Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
      • Saint Petersburg, Ryssland, 197341
        • Avslutad
        • Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
      • Saint Petersburg, Ryssland, 197758
        • Avslutad
        • Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
      • Saint Petersburg, Ryssland, 198255
        • Avslutad
        • Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
      • Yaroslavl, Ryssland, 150054
        • Avslutad
        • State Budgetary Healthcare Institution of the Yaroslavl Region
    • Sankt-Peterburg
      • Pushkin, Sankt-Peterburg, Ryssland, 196603
        • Aktiv, inte rekryterande
        • Private Medical Institution "Euromedservice"
      • Barcelona, Spanien, 08035
        • Rekrytering
        • Hospital Universitari Vall d'Hebron
      • Barcelona, Spanien, 08036
        • Rekrytering
        • Hospital Clinic de Barcelona
      • Barcelona, Spanien, 08023
        • Rekrytering
        • Hospital Quironsalud Barcelona
      • Madrid, Spanien, 28034
        • Rekrytering
        • Hospital Universitario Ramon y Cajal
      • Madrid, Spanien, 28050
        • Rekrytering
        • Hospital Universitario HM Sanchinarro
      • Madrid, Spanien, 28040
        • Rekrytering
        • H.U. Fundación Jiménez Díaz
      • Madrid, Spanien, 28041
        • Rekrytering
        • Hospital Universitario 12 De Octubre
      • Málaga, Spanien, 29010
        • Rekrytering
        • Hospital Universitario Virgen de la Victoria
      • Valencia, Spanien, 46026
        • Aktiv, inte rekryterande
        • Hospital Universitari i Politecnic La Fe
    • Barecelona
      • L'Hospitalet de Llobregat, Barecelona, Spanien, 08908
        • Aktiv, inte rekryterande
        • Institut Català d´Oncología (ICO)-H. Durán i Reynals
    • Castellon
      • Castellon, Castellon, Spanien, 12002
        • Aktiv, inte rekryterande
        • Consorcio Hospitalario Provincial de Castellon
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spanien, 28223
        • Rekrytering
        • Hospital Quironsalud Madrid
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spanien, 28040
        • Rekrytering
        • Hospital Clinico San Carlos
    • Kyǒnggi-do
      • Seongnam, Kyǒnggi-do, Sydkorea, 13620
        • Rekrytering
        • Seoul National University Bundang Hospital
    • Seoul-teukbyeolsi [seoul]
      • Seoul, Seoul-teukbyeolsi [seoul], Sydkorea, 03080
        • Aktiv, inte rekryterande
        • Seoul National University Hospital
      • Seoul, Seoul-teukbyeolsi [seoul], Sydkorea, 07985
        • Aktiv, inte rekryterande
        • Ewha Womans University Mokdong Hospital
      • Seoul, Seoul-teukbyeolsi [seoul], Sydkorea, 03722
        • Aktiv, inte rekryterande
        • Severance Hospital, Yonsei University Health System
    • Taejǒn-kwangyǒkshi
      • Daejeon, Taejǒn-kwangyǒkshi, Sydkorea, 35015
        • Aktiv, inte rekryterande
        • Chungnam national university hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Part 1 and Part 2 (Closed for enrollment).

Part 3 Key Inclusion Criteria:

  • Histological or cytological diagnosis of castration resistant prostate cancer.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
  • Adequate bone marrow, renal, and liver function

Part 3 Key Exclusion Criteria:

  • Prior irradiation to >25% of the bone marrow.
  • QTcF interval >480 msec at screening.
  • Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
  • Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
  • Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
  • Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
  • Prior enzalutamide within the last 4 weeks
  • DDI SUBSTUDY:
  • history of CHF or evidence of ventricular dysfunction
  • fructose intolerance
  • coadministration of CYP3A4 substrates
  • Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dose Escalation (Part 1A)

Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels

Oral continuous

Andra namn:
  • EZH2i
Experimentell: Dose Escalation (Part 1B)

Participants with FL will receive mevrometostat at escalating dose levels

Oral continuous

Andra namn:
  • EZH2i
Experimentell: Dose Escalation (Part 1C)

Participants with mCRPC will receive mevrometostat at escalating dose levels.

Oral continuous

Andra namn:
  • EZH2i
Experimentell: Dose Escalation (Part 2A)

Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC.

Oral continuous

Andra namn:
  • EZH2i

Oral continuous

Andra namn:
  • Xtandi
Experimentell: Dose Expansion (Part 2B)

Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone.

Oral continuous

Andra namn:
  • EZH2i

Oral continuous

Andra namn:
  • Xtandi
Experimentell: Japan Cohort

Participants with CRPC will receive mevrometostat at one or two doses

Oral continuous

Andra namn:
  • EZH2i
Experimentell: China cohort

Participants will receive mevrometostat at one or two doses

Oral continuous

Andra namn:
  • EZH2i
Experimentell: Dose Expansion (Part 2C)

Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC

Oral continuous

Andra namn:
  • EZH2i

Oral continuous

Andra namn:
  • Xtandi
Experimentell: BE Substudy

In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

Andra namn:
  • EZH2i

Oral continuous

Andra namn:
  • Xtandi
Experimentell: DDI Substudy

The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

Andra namn:
  • EZH2i

Oral continuous

Andra namn:
  • Xtandi

Oral solution

Andra namn:
  • Sporanox
  • Tolsura
  • Onmel

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Tidsram: Baseline up to 90 days

First cycle DLTs will be utilized to determine the MTD

Baseline up to 90 days
Overall safety profile including adverse events
Tidsram: Baseline up to approximately 2 years

Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03])

Baseline up to approximately 2 years
Preliminary efficacy determination as evaluated by disease specific response criteria
Tidsram: Through study completion, approximately 2 years past last patient first visit.

Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC.

Through study completion, approximately 2 years past last patient first visit.
Overall safety profile including laboratory abnormalities
Tidsram: Baseline up to approximately 2 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing.

Baseline up to approximately 2 years
Overall safety profile including vital signs
Tidsram: Baseline up to approximately 2 years

Vital sign changes from baseline including blood pressure, heart rate, ECG changes.

Baseline up to approximately 2 years
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Tidsram: Baseline until disease progression or death or through study completion (approx 2 years)

PCWG3

Baseline until disease progression or death or through study completion (approx 2 years)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Tidsram: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.

Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC)

Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
Evaluate overall survival
Tidsram: Baseline up to approximately 2 years

Median time to death proportion of patients alive at 6 months, 1 year, and 2 years.

Baseline up to approximately 2 years
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Tidsram: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tidsram: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Tidsram: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Tidsram: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Tidsram: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Tidsram: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Singe dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Evaluate the impact of mevrometostat on patient reported outcomes.
Tidsram: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.

Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P.

At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Tidsram: At specific time points from Cycle1 Day 1 to end of treatment

Questionnaire customized from PRO-CTCAE.

At specific time points from Cycle1 Day 1 to end of treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: Pfizer CT.gov Call Center, Pfizer

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

17 april 2018

Primärt slutförande (Beräknad)

20 april 2028

Avslutad studie (Beräknad)

7 juli 2029

Studieregistreringsdatum

Först inskickad

12 februari 2018

Först inskickad som uppfyllde QC-kriterierna

2 mars 2018

Första postat (Faktisk)

9 mars 2018

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera